

IPSOGEN GRANTS AN EXCLUSIVE LICENSE TO WARNEX TO MARKET A LEUKEMIA MOLECULAR DIAGNOSTIC SERVICE IN CANADA

Marseille, France, August 14, 2007 – Ipsogen SAS, today announced the signature of an exclusive agreement with Warnex Inc. (TSX: WNX), a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. According to the terms of the agreement, Ipsogen grants Warnex exclusive rights, for the Canadian territory, to market a service for the diagnosis and the classification of a group of leukemias.

“Identifying and commercializing cancer biomarkers carrying high value medical information is the core business of Ipsogen’s development strategy,” said Vincent Fert, President and CEO of Ipsogen. “The medical community is now eager to integrate the JAK2 test into clinical practice. Ipsogen has recently launched the test both in the form of a product and a licensing program to react rapidly to these urgent medical needs. Warnex, with its strong position in the Canadian molecular diagnostic services market, is the ideal partner to help Ipsogen establish its leadership in Canada.”

The service is based on the analysis of variations in the JAK2 gene, for which Ipsogen has exclusive worldwide intellectual property rights. A high proportion of patients with myeloproliferative disorders (MPD; polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis) carry a dominant gain-of-function V617F mutation in the JH2 kinase-like domain of JAK2. This pioneering work published in a 2005 issue of Nature by the INSERM team of Dr. Vainchenker (Institut Gustave Roussy, Paris) provides breakthrough progress for the molecular classification and the diagnosis of myeloproliferative disorders.

“Our reputation in the Canadian medical testing market as well as our scientific and medical credibility makes us an ideal recipient of Ipsogen’s exclusive license,” said Mark Busgang, President and CEO of Warnex. “In addition to expanding our service offering in medical testing, this license provides Warnex with the exclusivity for JAK2 clinical testing performed in Canada, thus significantly enhancing our market position. Finding the JAK2 mutation is a major step forward in diagnosing myeloproliferative disorders for the well-being of all Canadians.”

About Ipsogen

IPSOGEN is a molecular diagnostic company focused on the development and commercialization of innovative diagnostic products to guide treatment options in cancer. IPSOGEN has built a comprehensive portfolio of unique products in blood cancers available in over 50 countries all over the world to leading institutions involved in cancer care. IPSOGEN products are registered as IVD in Europe.

Leveraging its expertise in blood cancers, IPSOGEN has developed, in partnership with leading cancer institutions, a pipeline of diagnostic products in breast cancer.

IPSOGEN is headquartered in Marseille, France and has its U.S. offices in New Haven, Connecticut. For more information on IPSOGEN, please visit: <http://www.ipsogen.com>.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex’s analytical

services division provides pharmaceutical and biotechnology companies with a variety of quality control services, including traditional chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex's bioanalytical services division specializes in bioequivalence and bioavailability studies for clinical trials. Warnex's medical laboratories division focuses on genetic and biochemical testing for the healthcare industry and has extensive expertise in genetic testing for human identification, molecular diagnostics, and pharmacogenetics.

CONTACTS

Ipsogen: Vincent FERT, President & CEO - Tel +33 4 91293090 - fert@ipsogen.com

Global Headquarters

Ipsogen SAS
Luminy Biotech Entreprises
Case 923 - 163 Ave de Luminy
13288 Marseille
France

Tel: +33 4 91 29 30 90
Fax: +33 4 91 29 30 99
infos@ipsogen.com

North America - Oncodiagnosics

Ipsogen, Inc
300 George Street
New Haven
Connecticut 06511
USA

Tel: +1 203 285-6171
Fax: +1 203 285-6173
infos@ipsogen.com